AlphAIalphai — Financial news for AI agents
tradingview.comJUL 311 min read$VMD

VMD Q2'26 Earnings: EPS estimate is 0.12 USD

Viemed Healthcare, Inc. (VMD) is scheduled to report Q2 2026 earnings on Aug. 3 at 8:00 AM ET. The consensus outlook cited for Q2 2026 calls for revenue of $78.0 million and EPS of $0.12, with figures stated in USD.

Original reporting
tradingview.com
Published Jul 31, 2026, 11:00 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 31, 2026, 9:11 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
VMD Q2'26 Earnings: EPS estimate is 0.12 USD — source image
Source · tradingview.com
Decision brief

The 30-second read

$VMDNeutralMed
01

Why it matters

Traders can use the consensus $78.0M revenue and $0.12 EPS to frame expectations and scenario-plan for upside/downside into the Aug 3 release.

02

Market read

Provides a concrete earnings date and consensus figures that can guide positioning and options/volatility expectations into the print.

03

What to watch

The article does not include management guidance, backlog, or any risk factors, which are often the true drivers of post-earnings repricing.

Relevance 5/10Novelty 5/10Timing: ahead of Aug 3 pre-market earnings release

Background

The piece is a pre-announcement note for VMD’s upcoming Q2'26 earnings, including consensus revenue and EPS.

Company-level read

Ticker impact

$VMDNeutralMedium confidence
Context

VMD is scheduled to announce Q2'26 results on Aug 3, with consensus revenue of $78.0M and EPS of $0.12.

Expected impact

Moderate volatility possible into Aug 3 as traders position around the $78.0M revenue and $0.12 EPS consensus.

Evidence & confidence

The article provides only the scheduled earnings date and consensus estimates, with no surprise datapoint beyond what traders typically price in ahead of results.

Market effects

Sector

Limited sector read-through because the article contains only company-specific consensus estimates.

Regional

No explicit regional market linkage provided.

Global

No global macro or cross-border catalyst mentioned.

Counterpoint

What could challenge this read

If VMD’s actual results diverge materially from the $78.0M/$0.12 consensus, the stock reaction could be driven more by guidance and margins than by the headline EPS.

Key entities

  • company
    VMD

    Viemed Healthcare, Inc., scheduled to report Q2'26 results on Aug 3 with consensus estimates provided.

Read at source← All news

Related articles

AUG 20
Med

Viemed Healthcare Announces New Share Repurchase Program of Up to 5% of Shares Outstanding – Minichart

Viemed Healthcare reported Q2 2026 revenue of $78.1M (up 24% Y-o-Y) and Adjusted EBITDA of $13.7M. The company announced a new share repurchase program for up to 5% of outstanding shares, following a strong first half with 680,802 shares repurchased. Full-year 2026 guidance is $314M-$320M in revenue and $64M-$68M in Adjusted EBITDA. The company has a strong balance sheet with $10.7M in cash and no net debt as of June 30, 2026.

minichart.com.sg2 min
AUG 11
$VMDMedAI 8/10

Viemed (VMD) Q2 2026 Earnings Call Transcript

Viemed Healthcare (VMD) reported Q2 2026 revenue of $78.1M, up 24% year over year, with ventilator patient counts reaching 12,635. Adjusted EBITDA was $13.7M (17.6% margin) and net income was $2.8M. Full-year 2026 revenue guidance was raised to $314M-$320M and adjusted EBITDA to $64M-$68M.

fool.com6 min
AUG 6
$VMDMedAI 8/10

Viemed Healthcare Q2 Earnings Call Highlights

Viemed Healthcare (NASDAQ:VMD) reported Q2 updates on home respiratory and sleep therapies. Management cited improved ventilator patient growth and said PAP setups rose, with sleep patients up about 5% sequentially and 44% YoY. Equipment sales nearly doubled to $19M. Gross profit was $45M (57.7% margin). Full-year net revenue guidance raised to $314M-$320M and adjusted EBITDA to $64M-$68M.

yahoo.com6 min
AUG 3
$VMDHigh

VIEMED HEALTHCARE, INC. (VMD): Results of Operations and Financial Condition

VIEMED HEALTHCARE, INC. (VMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. VIEMED HEALTHCARE ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS Lafayette, Louisiana (August 3, 2026) Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national provider of technology-enabled, home-based healthcare solutions and chronic disease management, ann

SEC EDGAR 8-K6 min
AUG 28
$HIMSHighAI 8/10

Hims & Hers (HIMS) CEO Says the FTC Doesn’t Understand His Own Company

Hims & Hers (HIMS) CEO Andrew Dudum defended the company against an FTC lawsuit, citing its revenue growth and subscriber base. Q2 revenue rose 40% YoY to $753M, with a full-year forecast of $3.1B-$3.3B. However, margins fell to 64% from 76%, and free cash flow was negative $68M, raising concerns about profitability and legal risks.

yahoo.com2 min